Koriath, C. http://orcid.org/0000-0003-1066-4938
Kenny, J.
Adamson, G.
Druyeh, R.
Taylor, W.
Beck, J.
Quinn, L.
Mok, T. H.
Dimitriadis, A.
Norsworthy, P. http://orcid.org/0000-0002-5572-8491
Bass, N.
Carter, J.
Walker, Z.
Kipps, C.
Coulthard, E.
Polke, J. M.
Bernal-Quiros, M.
Denning, N.
Thomas, R.
Raybould, R.
Williams, J.
Mummery, C. J.
Wild, E. J. http://orcid.org/0000-0002-6921-7887
Houlden, H. http://orcid.org/0000-0002-2866-7777
Tabrizi, S. J.
Rossor, M. N.
Hummerich, H.
Warren, J. D.
Rowe, J. B.
Rohrer, J. D.
Schott, J. M. http://orcid.org/0000-0003-2059-024X
Fox, N. C.
Collinge, J.
Mead, S.
Funding for this research was provided by:
Medical Research Council (Prion Unit funding)
Article History
Received: 26 January 2018
Revised: 28 June 2018
Accepted: 18 July 2018
First Online: 2 October 2018
Compliance with ethical standards
:
: Through UCL Consultants Ltd, a wholly owned subsidiary of University College London, EJW has served on scientific advisory boards for Novartis, F Hoffmann-La Roche, Ionis, Shire, Wave Life Sciences, PTC Therapeutics and Mitoconix.Prof Collinge is a director and shareholder of D-Gen Limited (London), an academic spinout company working in the field of prion disease diagnosis, decontamination, and therapeutics.None of the other authors report any conflict of interest.